http://ift.tt/11PzBth
Amgen Inc. said it ended clinical studies of a treatment for advanced stomach cancer based on safety concerns.
The biopharmaceutical company said an independent data-monitoring committee found an increase in the number of deaths in patients using a combination of the experimental drug—rilotumumab—and chemotherapy, compared with the arm that received only chemotherapy treatment.
“While we are disappointed with these results, we will work with lead investigators to further analyze the data in order to help inform future research and therapies in this area,” said Sean E. Harper, Amgen executive vice president of research and development.
First Trebananib, now this. That's 2 oncology failures in one month. I guess all Amgen will ever be is a bunch of supportive care hacks.
-- The Real Oncology Therapeutic Companies of (Celegene, Genentech, Medivation, JnJ, Novartis)
Amgen Inc. said it ended clinical studies of a treatment for advanced stomach cancer based on safety concerns.
The biopharmaceutical company said an independent data-monitoring committee found an increase in the number of deaths in patients using a combination of the experimental drug—rilotumumab—and chemotherapy, compared with the arm that received only chemotherapy treatment.
“While we are disappointed with these results, we will work with lead investigators to further analyze the data in order to help inform future research and therapies in this area,” said Sean E. Harper, Amgen executive vice president of research and development.
First Trebananib, now this. That's 2 oncology failures in one month. I guess all Amgen will ever be is a bunch of supportive care hacks.
-- The Real Oncology Therapeutic Companies of (Celegene, Genentech, Medivation, JnJ, Novartis)
Another Amgen Oncology Failure
Aucun commentaire:
Enregistrer un commentaire